BioLineRX Ltd
BLRXStock
$2.98+136.20%52W
Market Cap$39.31M
P/E—
Div yield—
Beta0.74
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-20.70%
Price vs S&P 500 (4W)-1.00%
VGM Score45.31
Market Capitalization$39.31M
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BLRXBioLineRX Ltd | B | F | B | $2.98 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
BioLine Rx is a commercial-stage biopharmaceutical company developing oncology-focused therapies. The company's pipeline includes two clinical-stage candidates: motixafortide (BL-8040), a peptide targeting stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent for solid tumors. The company also maintains a legacy product, BL-5010, for skin lesions, and has generated revenue through milestone payments and out-licensing agreements.